Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy.
In order to evaluate the efficacy of combined immunochemotherapy with mitomycin-C, tegafur, PSK and/or OK-432 as an adjunct for curatively resected gastric cancer, a prospective randomized controlled study using the envelope method was performed, in which 266 institutions from around Japan participated. The 3 year survival rates for all cases, and for ps(+).n(+) cases, were insignificantly higher in the immunochemotherapy groups receiving PSK and/or OK-432 than in the control group. However, because 28.2 per cent of the cases were excluded from the final statistical analyses, the results of this study may have questionable statistical credibility. Changes in the stimulation index (SI) suggest that the administration of PSK may result in an inhibition of the immunosuppressive activity of cancer patients. The high SI group showed a significantly higher 4 year survival rate than the low SI group.
Hattori
T
T
Shakai-Hoken Nakabaru Hospital, Fukuoka, Japan.
Nakajima
T
T
Nakazato
H
H
Tanabe
T
T
Kikuchi
K
K
Abe
O
O
Kondo
T
T
Taguchi
T
T
Komi
N
N
Sugimachi
K
K
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D010844:Picibanil / Q000008:administration & dosage; D011182:Postoperative Care; D011446:Prospective Studies; D011509:Proteoglycans / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D011509:Proteoglycans; D005641:Tegafur; D010844:Picibanil; C010770:polysaccharide-K; D016685:Mitomycin